| P2093 | author name string | Earl R Kern | |
| | Caroll B Hartline | |
| | Mark N Prichard | |
| | Debra C Quenelle | |
| | E Randall Lanier | |
| P2860 | cites work | Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. | Q37401749 |
| | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides | Q37450711 |
| | Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir | Q37488882 |
| | Current status and challenges of antiretroviral research and therapy | Q37657867 |
| | Antiretroviral therapy and management of HIV infection | Q37770721 |
| | A three-dimensional model to analyze drug-drug interactions | Q37794779 |
| | Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model | Q38460330 |
| | Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. | Q38482641 |
| | Mechanism of action and selectivity of acyclovir | Q40130389 |
| | Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. | Q43749186 |
| | Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial | Q43886317 |
| | Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice | Q44878718 |
| | Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. | Q44970891 |
| | Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract | Q45066119 |
| | Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization | Q45168406 |
| | The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice | Q45747997 |
| | Vidarabine versus acyclovir therapy in herpes simplex encephalitis | Q48385636 |
| | Effect of acyclovir treatment on acute and chronic murine cytomegalovirus infection | Q72938743 |
| | Safety and Efficacy of High-Dose Intravenous Acyclovir in the Management of Neonatal Herpes Simplex Virus Infections | Q22305966 |
| | The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia | Q24523533 |
| | Efficacy of CMX001 against Herpes Simplex Virus Infections in Mice and Correlations with Drug Distribution Studies | Q24629979 |
| | Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency | Q28273745 |
| | Persistence of herpes simplex virus DNA in cerebrospinal fluid of neonates with herpes simplex virus encephalitis. | Q33405731 |
| | Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function | Q33676105 |
| | The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation | Q33784836 |
| | Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro | Q33935329 |
| | Current recommendations for the treatment of genital herpes. | Q34127423 |
| | Once-daily valacyclovir to reduce the risk of transmission of genital herpes | Q34287411 |
| | Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections | Q34510424 |
| | Herpes simplex virus resistance to antiviral drugs | Q34531396 |
| | Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy | Q34579981 |
| | Recurrent antiviral-resistant genital herpes in an immunocompetent patient | Q34698957 |
| | Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms | Q34756486 |
| | Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir | Q34918273 |
| | Progress in meeting today's demands in genital herpes: an overview of current management | Q34918299 |
| | Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. | Q35547866 |
| | Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses | Q36295446 |
| | Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management. | Q36478736 |
| | Management of HSV encephalitis in adults and neonates: diagnosis, prognosis and treatment. | Q36937380 |
| | Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. | Q37283124 |
| | Novel approaches in fighting herpes simplex virus infections | Q37316071 |
| | Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection | Q37357122 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aciclovir | Q147101 |
| P304 | page(s) | 4728-4734 | |
| P577 | publication date | 2011-07-25 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections | |
| P478 | volume | 55 | |